# US 2022/0016098 A1 · Orally administered pharmaceutical composition comprising fab i inhibitors and method for preparing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0016098 A1
- Document ID: US20220016098A1
- Status: Published application
- Kind: A1
- Application number: 17/258,954
- Filed: 2019-05-29
- Published: 2022-01-20
- Earliest claimed: 2018-07-20
- Assignees: CrystalGenomics, Inc.
- Applicants: Crystalgenomics, Inc.
- Inventors: Jae Pyoung CHO; Joong Myung CHO
- Web page: https://patentgrep.com/patent/US20220016098A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/4436: containing a heterocyclic ring having sulfur as a ring hetero atom
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2095: {Tabletting processes}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 9/4833: {Encapsulating processes; Filling of capsules (mechanical aspects A61J3/07)}
- A61K 9/4858: {Organic compounds}
- A61P 31/04: Antibacterial agents
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to an orally administered pharmaceutical composition comprising Fab I inhibitors, and to a method for preparing same. The present invention may be applied effectively to bacterial infections resistant to antibiotics and the like. More specifically, the present invention can more rapidly initiate therapeutic effects by improving dissolution and elution rates. Furthermore, the present invention can improve the mixing and content uniformity in preparations by regulating the particle size.

## Claims

### Claim 1

A pharmaceutical composition for oral administration comprising 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof has a particle size distribution D90 of 0.1 to 500 μm.

### Claim 3 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the composition is provided in the form of a tablet or capsule.

### Claim 4 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the 1-(3-amino-2-methylbenzyl)-4-(2-thiophen-2-yl-ethoxy)-1H-pyridin-2-one or a salt thereof or both of them is present in an amount of 10 to 60% by weight based on the total weight of the composition.

### Claim 5

A method for preparing a pharmaceutical composition for oral administration, comprising:
adding 4-benzyloxy-1H-pyridone, 2-methyl-3-nitro-benzylchloride and potassium tert-butoxide to dimethylformamide, and mixing them to react with heating;
adding purified water and drying with heating to obtain a dried product;
dissolving the dried product in an organic solvent and adding purified water for layer separation;
recovering the organic layer to filter and concentrate it to obtain concentrates;
re-concentrating the concentrates and adding hexane to obtain precipitates;
dissolving the resulting precipitates, and cooling, filtering and drying them to obtain a dried product; and
dissolving the resulting dried product in an organic solvent, adding iron chloride hexahydrate, activated carbon and hydrazine monohydrate thereto, cooling and filtrating them to obtain resulting precipitates and then drying and pulverizing it.

### Claim 6 (depends on 5)

The method for preparing a pharmaceutical composition for oral administration according to claim 5, wherein the method further comprises adding an acidic substance.

### Claim 7 (depends on 6)

The method for preparing a pharmaceutical composition for oral administration according to claim 6, wherein the acidic substance includes hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, oxalic acid, fumaric acid, malonic acid, maleic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, EDTA, and combinations thereof.

### Claim 8 (depends on 5)

The method for preparing a pharmaceutical composition for oral administration according to claim 5, wherein the precipitates are formulated into a tablet containing nanoparticles or a capsule containing solid dispersion particles.

### Claim 9 (depends on 1)

The pharmaceutical composition for oral administration according to claim 1, wherein the composition is used for the treatment of bacterial infections.
